In a recent meta-analysis of 39 randomized controlled trials involving people with obesity and/or type 2 diabetes, a trend towards a reduction in the risk of asthma was recorded in users of GLP-1 receptor agonists compared to non-users. Here, GLP1R is linked to asthma.